-
1 month ago | 
healio.com | Scott Buzby |Gregg C. Fonarow |Richard Smith
Q&A: ‘Normal’ blood glucose may still increase risk for heart disease• Elevated but “normal” blood glucose may be a target for cardiovascular disease risk reduction. • Researchers proposed newly reclassified stages for plasma glucose as it relates to heart disease risk. Slightly elevated blood glucose within a range of what is generally considered “normal” may be associated with increased risk for heart disease, researchers reported. Gregg C.
-
Jan 10, 2025 | 
healio.com | Scott Buzby |Richard Smith |Clyde Yancy |Gregg C. Fonarow
Polypills may be cost-effective for CVD prevention in underserved US communities• A polypill-based strategy may be cost-effective for primary CVD prevention in historically underserved communities. • The estimated cost was $8,560 to $13,400 per quality-adjusted life-year gained. A daily polypill was estimated to be cost-effective for primary CVD prevention among U.S. adults living in historically underserved communities with limited health care access and low income, researchers reported.
-
Nov 17, 2024 | 
jamanetwork.com | Sadiya Khan |Gregg C. Fonarow
Sex-Specific Efficacy and Safety in HF Trials: Inclusion Is Only the First Step
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Misato Chimura, MD, PhD; Xiaowen Wang, MD, MPH; Pardeep S. Jhund, MBChB, MSc, PhD; Alasdair D. Henderson, PhD; Brian L. Claggett, PhD; Akshay S.
-
Nov 17, 2024 | 
jamanetwork.com | Gregg C. Fonarow |Eric Peterson |Adrian Hernandez |Adrián Hernández
The Fine Art and Science of Translating Trials Results Into Clinical Practice Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure Orly Vardeny, PharmD, MS; Muthiah Vaduganathan, MD, MPH; Brian L. Claggett, PhD; Akshay S. Desai, MD, MPH; Pardeep S. Jhund, MBChB, MSc, PhD; Carolyn S. P. Lam, MBBS, PhD; Michele Senni, MD; Sanjiv J. Shah, MD; Adriaan A.
-
Nov 15, 2024 | 
jamanetwork.com | James E. Udelson |Clyde Yancy |Gregg C. Fonarow
Interpreting Health Status Measures in Patients With Heart Failure—What Counts Interpreting Population Mean Treatment Effects in the Kansas City Cardiomyopathy Questionnaire Mohammad Abdel Jawad, MD; Philip G. Jones, MS; Suzanne V. Arnold, MD, MHA; David J. Cohen, MD, MSc; Charles F. Sherrod, MD; Mirza S. Khan, MD; Nobuhiro Ikemura, MD, PhD; Paul S. Chan, MD, MSc; John A.
-
Nov 6, 2024 | 
jamanetwork.com | Gregg C. Fonarow |James E. Udelson |Clyde Yancy
Heart Failure With Preserved Ejection Fraction—A Role for Invasive Hemodynamics Prevalence of HFpEF in Isolated Severe Secondary Tricuspid Regurgitation Jwan A. Naser, MBBS; Tomonari Harada, MD, PhD; Yogesh N. Reddy, MBBS; Sorin V. Pislaru, MD, PhD; Hector I. Michelena, MD; Christopher G. Scott, MS; Austin M. Kennedy, BS; Patricia A. Pellikka, MD; Vuyisile T. Nkomo, MD, MPH; Mackram F. Eleid, MD; Barry A.
-
Oct 31, 2024 | 
jamanetwork.com | Jacob Pierce |Muthiah Vaduganathan |Gregg C. Fonarow |Uchechukwu Ikeaba
Key PointsQuestion What is the prevalence and variability of sodium-glucose cotransporter-2 inhibitor (SGLT2i) use among patients with heart failure with reduced ejection fraction (HFrEF) in the US? Findings In this cohort study including 49 399 patients hospitalized for HFrEF in the Get With The Guidelines–Heart Failure registry, 1 in 5 patients were discharged with prescriptions for SGLT2i therapy; rates were similarly low in patients with comorbid type 2 diabetes and chronic kidney disease.
-
Oct 16, 2024 | 
jamanetwork.com | Gregg C. Fonarow
Parsing Signal vs Noise—Secondary Analyses of RCTs
Coronary Revascularization Guided With Fractional Flow Reserve or Instantaneous Wave-Free Ratio
Javier Escaned, MD, PhD; Alejandro Travieso, MD; Hakim-Moulay Dehbi, PhD; Sukhjinder S. Nijjer, MD, PhD; Sayan Sen, MD, PhD; Ricardo Petraco, MD, PhD; Manesh Patel, MD; Patrick W.
-
Oct 2, 2024 | 
jamanetwork.com | Amber Tang |Baylor Scott |Gregg C. Fonarow
Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure
Key PointsQuestion
What is the potential number of lives saved with optimal implementation of quadruple guideline-directed medical therapy (GDMT) on a global level?
-
Aug 7, 2024 | 
jamanetwork.com | Gregg C. Fonarow |Kristen K. Patton
Changing the Frame of Post-AMI Left Ventricular Dysfunction: Sudden Cardiac Death, a Diminishing Complication
Rates of Sudden Death After Myocardial Infarction—VALIANT and PARADISE-MI Trials
James P. Curtain, MB, BS; Marc A. Pfeffer, PhD; Eugene Braunwald, MD; Brian L. Claggett, PhD; Christopher B. Granger, MD; Lars Køber, MD, DSci; Eldrin F. Lewis, MD, MPH; Aldo P. Maggioni, MD; Doug L. Mann, MD; Jean L. Rouleau, MD; Scott D.
